Show simple item record

Design and synthesis of small molecule ligands targeting protease-activated receptor 2 as potential diagnostic and therapeutic agents

dc.contributor.advisorHou, Jinqiang
dc.contributor.authorMao, Yang
dc.date.accessioned2021-09-20T20:34:00Z
dc.date.available2021-09-20T20:34:00Z
dc.date.created2021
dc.date.issued2021
dc.identifier.urihttps://knowledgecommons.lakeheadu.ca/handle/2453/4855
dc.description.abstractPositron emission tomography (PET) imaging requires radionuclides (positron-emitters) labeled molecules (tracers) to image biochemical and physiological processes in vivo and helps diagnose diseases noninvasively. The success of PET imaging depends on validated radiopharmaceuticals targeting biologically relevant receptors. Protease-activated receptors (PARs) are cell membrane receptors that belong to a class of the G protein-coupled receptors (GPCRs) family. Proteaseactivated receptor 2 (PAR2) is the second member of the PARs family. Aberrant activation of PAR2 is associated with various cancers, through downstream signaling that contributes to cancer progression and tumor metastasis. It has been found that PAR2 exhibited up to 16-fold overexpression in lung cancer. The upregulation of PAR2 in cancers indicates that it may serve as potential drug target for cancer screening and treatment. Blocking PAR2 activity with small molecules is proposed to provide a therapeutic benefit. In addition, the development of 18Fradiolabeled small molecules targeting PAR2 receptor hasthe potential to non-invasively diagnose some types of cancers such as lung and breast cancers. A library of AZ3451 analogues (14 compounds) was designed with the assistance of molecular modelling, and was synthesized, and characterized by Mass Spectrometry, and 1H-NMR. All compounds have greater than 95% purity as confirmed by HPLC. Collaborator Dr. Rithwik Ramachandran at Western University (UWO) will perform functional assays including calcium-signalling, β-arrestin recruitment, MARK signaling assays etc. to evaluate all compounds for the therapeutic potential; the candidate molecule will be selected for radiolabelling and PET imaging studies using animal models of cancer at the TBRHRI. The novel compounds synthesized in the thesis are potentially useful for the treatment of PAR2-driven cancers while the radioligand has potential for non-invasive cancer diagnosis with PET.en_US
dc.language.isoen_USen_US
dc.subjectPositron emission tomography (PET)en_US
dc.subjectPET imaging agenten_US
dc.subjectRadiopharmaceuticalsen_US
dc.subjectG protein-coupled receptoren_US
dc.subjectInflammatory diseasesen_US
dc.subjectCancer and molecular imagingen_US
dc.titleDesign and synthesis of small molecule ligands targeting protease-activated receptor 2 as potential diagnostic and therapeutic agentsen_US
dc.typeThesisen_US
etd.degree.nameMaster of Scienceen_US
etd.degree.levelMasteren_US
etd.degree.disciplineChemistryen_US
etd.degree.grantorLakehead Universityen_US
dc.contributor.committeememberCampbell, Michael
dc.contributor.committeememberGottardo, Christine


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record